Studies confirmed that FSIP1 directly binded to HER2 and inhibited the expression of multiple growth factors in HER2-positive breast cancer cells, leading to a decrease in cell proliferation, cell migration, and invasion capabilities and an increase in apoptosis. This evidence concerns the gene ERBB2 and breast cancer.